31793209|t|Melatonin protects against ischemic stroke by modulating microglia/macrophage polarization toward anti-inflammatory phenotype through STAT3 pathway.
31793209|a|AIMS: Microglia and infiltrated macrophages play important roles in inflammatory processes after ischemic stroke. Modulating microglia/macrophage polarization from pro-inflammatory phenotype to anti-inflammatory state has been suggested as a potential therapeutic approach in the treatment of ischemic stroke. Melatonin has been shown to be neuroprotective in experimental stroke models. However, the effect of melatonin on microglia polarization after stroke and underlying mechanisms remain unknown. METHODS: In vivo, cerebral ischemia was induced by distal middle cerebral artery occlusion (dMCAO) in C57BL/6J mice. Melatonin was injected intraperitoneally (20 mg/kg) at 0 and 24 hours after ischemia. In vitro, the microglial cell line BV2 was stimulated to the pro-inflammatory state with conditioned media (CM) collected from oxygen-glucose deprivation (OGD) challenged neuronal cell line Neuro-2a (N2a). Real-time PCR was utilized to detect the mRNA expression of microglia phenotype markers. Activation of signal transducer and activator of transcription 3 (STAT3) pathway was determined by Western blot of phosphorylated STAT3 (pSTAT3). A neuron-microglia co-culture system was used to determine whether melatonin can inhibit the neurotoxic effect of pro-inflammatory microglia to post-OGD neurons. RESULTS: Melatonin treatment reduced brain infarct and improved neurological functions 3 days after dMCAO, which was accompanied by decreased expression of pro-inflammatory markers and increased expression of anti-inflammatory markers in the ischemic brain. In vitro studies confirmed that melatonin directly inhibited the pro-inflammatory responses in BV2 cells upon exposure to OGD neuron CM. The microglia possessing pro-inflammatory phenotype exacerbated post-OGD N2a cells death, whereas melatonin reduced such neurotoxic effect. Further, melatonin enhanced the otherwise inhibited pSTAT3 expression in BV2 cells treated with OGD neuron CM. STAT3 blockade significantly reduced the effect of melatonin on microglial phenotype shift. CONCLUSION: Melatonin treatment ameliorates brain damage at least partially through shifting microglia phenotype from pro-inflammatory to anti-inflammatory polarity in a STAT3-dependent manner.
31793209	0	9	Melatonin	Chemical	MESH:D008550
31793209	27	42	ischemic stroke	Disease	MESH:D002544
31793209	103	115	inflammatory	Disease	MESH:D007249
31793209	134	139	STAT3	Gene	20848
31793209	217	229	inflammatory	Disease	MESH:D007249
31793209	246	261	ischemic stroke	Disease	MESH:D002544
31793209	317	329	inflammatory	Disease	MESH:D007249
31793209	348	360	inflammatory	Disease	MESH:D007249
31793209	442	457	ischemic stroke	Disease	MESH:D002544
31793209	459	468	Melatonin	Chemical	MESH:D008550
31793209	522	528	stroke	Disease	MESH:D020521
31793209	560	569	melatonin	Chemical	MESH:D008550
31793209	602	608	stroke	Disease	MESH:D020521
31793209	669	686	cerebral ischemia	Disease	MESH:D002545
31793209	709	741	middle cerebral artery occlusion	Disease	MESH:D020244
31793209	743	748	dMCAO	Disease	MESH:D020244
31793209	753	759	C57BL/	CellLine	CVCL:C152
31793209	762	766	mice	Species	10090
31793209	768	777	Melatonin	Chemical	MESH:D008550
31793209	844	852	ischemia	Disease	MESH:D007511
31793209	889	892	BV2	CellLine	CVCL:0182
31793209	919	931	inflammatory	Disease	MESH:D007249
31793209	981	987	oxygen	Chemical	MESH:D010100
31793209	988	995	glucose	Chemical	MESH:D005947
31793209	1044	1052	Neuro-2a	CellLine	CVCL:0470
31793209	1054	1057	N2a	CellLine	CVCL:0470
31793209	1163	1213	signal transducer and activator of transcription 3	Gene	20848
31793209	1215	1220	STAT3	Gene	20848
31793209	1279	1284	STAT3	Gene	20848
31793209	1362	1371	melatonin	Chemical	MESH:D008550
31793209	1388	1398	neurotoxic	Disease	MESH:D020258
31793209	1413	1425	inflammatory	Disease	MESH:D007249
31793209	1466	1475	Melatonin	Chemical	MESH:D008550
31793209	1494	1507	brain infarct	Disease	MESH:D020520
31793209	1557	1562	dMCAO	Disease	MESH:D020244
31793209	1617	1629	inflammatory	Disease	MESH:D007249
31793209	1671	1683	inflammatory	Disease	MESH:D007249
31793209	1699	1713	ischemic brain	Disease	MESH:D020520
31793209	1747	1756	melatonin	Chemical	MESH:D008550
31793209	1784	1796	inflammatory	Disease	MESH:D007249
31793209	1810	1813	BV2	CellLine	CVCL:0182
31793209	1881	1893	inflammatory	Disease	MESH:D007249
31793209	1925	1928	N2a	CellLine	CVCL:0470
31793209	1950	1959	melatonin	Chemical	MESH:D008550
31793209	1973	1983	neurotoxic	Disease	MESH:D020258
31793209	2001	2010	melatonin	Chemical	MESH:D008550
31793209	2065	2068	BV2	CellLine	CVCL:0182
31793209	2103	2108	STAT3	Gene	20848
31793209	2154	2163	melatonin	Chemical	MESH:D008550
31793209	2207	2216	Melatonin	Chemical	MESH:D008550
31793209	2239	2251	brain damage	Disease	MESH:D001925
31793209	2317	2329	inflammatory	Disease	MESH:D007249
31793209	2338	2350	inflammatory	Disease	MESH:D007249
31793209	2365	2370	STAT3	Gene	20848
31793209	Negative_Correlation	MESH:D008550	MESH:D001925
31793209	Negative_Correlation	MESH:D008550	MESH:D007249
31793209	Association	MESH:D001925	20848
31793209	Association	MESH:D007249	20848
31793209	Negative_Correlation	MESH:D008550	MESH:D020520
31793209	Negative_Correlation	MESH:D008550	MESH:D020258
31793209	Association	MESH:D008550	20848
31793209	Negative_Correlation	MESH:D008550	MESH:D020521
31793209	Negative_Correlation	MESH:D008550	MESH:D002544
31793209	Negative_Correlation	MESH:D008550	MESH:D020244

